BackMangoceuticals Overview

Mangoceuticals Minority Interest

Track Mangoceuticals's minority interest ($-2.1K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Minority Interest
$-2118.00
↑ 79.34% YoYΔ $-937.00 vs prior year quarter

Peer trimmed avg / median

Loading

Mangoceuticals Minority Interest History

Loading

Mangoceuticals vs. peers: Minority Interest Comparison

Loading

Mangoceuticals Minority Interest Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Mangoceuticals (MGRX) FAQ

Mangoceuticals posts a minority interest of $-2.1K as of June 2026. That compares with $-1.2K in the prior-year period — down 79.3% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Mangoceuticals's minority interest was $-1.2K. The latest reading is $-2.1K — a 79.3% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Minority Interest is one piece of Mangoceuticals's financial statement story. At $-2.1K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for MGRX's minority interest usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Mangoceuticals's other metric pages and overview cover the third.